Triamcinolone Acetonide Extended-Release Injectable Suspension (Zilretta)

Zilretta (triamcinolone acetonide extended‑release) is covered only as a single intra‑articular injection for the FDA‑approved indication of osteoarthritis pain of the knee; off‑label uses and repeat doses are not covered. Approval requires documentation of knee OA, no prior Zilretta exposure, and inadequate response/intolerance/contraindication to at least two of acetaminophen, NSAIDs, or tramadol plus inadequate response to a prior intra‑articular corticosteroid injection.

"Documentation that the patient has not previously received Zilretta injection"

Sign up to see full coverage criteria, indications, and limitations.